Search
Levosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan is under investigation in clinical trial NCT00527059 (Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure).
Categories: Compounds used in a research, industrial, or household settingProducts: LEVOSIMENDAN EG, DAXIM® 2.5 MG / MLProcaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedA local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
Categories: Esters of Aminobenzoic Acid, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseProducts: Novocain 20 mg/ml, NTCAIN 100 MG/10 ML IM AMPUL, 10 ADETNadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigationaloffer better rates of adverse effects. … [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]
Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MGProducts: NADOLOL MK 80 MG TABLETAS, CORGARD (NADOLOL) 80 MG TABLETASDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalDesvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. … Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD.
Categories: Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: O-desmethylvenlafaxineTrypsin
go.drugbank.com/drugs/DB11237ApprovedInvestigationalVet approvedTherapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is intended to aid in digestion when administered orally. … Trypsin also contains an oxyanion hole that stabilizes the charge negative charge on the carbonyl oxygen atom formed from the cleavage of peptide bonds.
Categories: Preparations for Treatment of Wounds and UlcersTalquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalon July 21, 2023. … [A260890] The Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended conditional marketing authorization for talquetamab for the treatment of relapsed or refractory multiple myeloma
Synonyms: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONALChlorotrianisene
go.drugbank.com/drugs/DB00269ApprovedWithdrawnA powerful synthetic, non-steroidal estrogen. [PubChem]
Categories: Sex Hormones and Modulators of the Genital SystemSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalOn January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Products: SUNITINIB EG, Sutent Capsule 25 mgSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It has once again been approved and should soon be available on the French and Australian market.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Serdolect 12 mg - Filmtabletten, Serdolect 16 mg - FilmtablettenMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative … [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.